2000 to 2019 Saw Rise in Breast Cancer Incidence in Young U.S. Women
30 Jan 2024
Clinical Result
TUESDAY, Jan. 30, 2024 -- There has been an increase in breast cancer incidence rates among young U.S. women from 2000 to 2019, according to a study published online Jan. 26 in JAMA Network Open.
Shuai Xu, M.P.H., from Washington University School of Medicine in St. Louis, and colleagues assessed recent trends and how period and cohort effects may affect trends in breast cancer incidence among young U.S. women (aged 20 to 49 years). The analysis included data from 217,815 women with a primary invasive breast cancer identified from the Surveillance, Epidemiology, and End Results registries (2000 to 2019).
The researchers found that the majority were diagnosed with an estrogen receptor (ER)-positive/progesterone receptor (PR)-positive tumor (61.5 percent) and were diagnosed with a stage I tumor (37.6 percent). There was an overall increase in incidence of invasive breast cancer (average annual percent changes [AAPC], 0.79), with similar trends seen across almost all racial and ethnic groups. Age-standardized incidence rates (ASIR) increased for ER-positive/PR-positive (AAPC, 2.72) and ER-positive/PR-negative tumors (AAPC, 1.43), but decreased for ER-negative/PR-positive tumors (AAPC, −3.25). ASIR were highest among non-Hispanic Black women (aged 20 to 29 years: incidence rate ratios [IRR], 1.53; aged 30 to 39 years: IRR, 1.15). However, for women aged 40 to 49 years, ASIR was lower for non-Hispanic Black women versus non-Hispanic White women (IRR, 0.96). Both cohort and period effects were seen on breast cancer incidence in an age-period-cohort analysis.
"These results suggest that understanding factors driving differential trends in incidence rates for different age groups by race and ER-positive status should provide insights into breast cancer prevention in young women," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.